Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy

Bibliography

• Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000;41:1364-74
   PubMed Web of Science ®Google Scholar
• Giussani G, Beghi E. Does mechanism of drug action matter to inform rational polytherapy in epilepsy? CNS Neurol Disord Drug Targets 2013;12:426-35
   PubMed Web of Science ®Google Scholar
• Łuszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009;61:197-216
   PubMed Web of Science ®Google Scholar
• Sperling M, Harvey JJ, Biraben A, et al. Adjunctive eslicarbazepine acetate in patients with refractory partial-onset seizures: efficacy results of a 12 week randomized placebo-controlled study (poster no. 3.210). In: 67th Annual American Epilepsy Society Meeting; 6 – 10 Dec 2013; Washington, DC
   Google Scholar
• Miziak B, Chrościńska-Krawczyk M, Błaszczyk B, et al. Novel approaches to anticonvulsant drug discovery. Expert Opin Drug Discov 2013;8:1415-27
   PubMed Web of Science ®Google Scholar
• Singh RP, Asconapé JJ. A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy. J Cent Nerv Syst Dis 2011;3:179-87
   Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004;61:1-48
   PubMed Web of Science ®Google Scholar
• Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999;42:2582-7
   PubMed Web of Science ®Google Scholar
• Hainzl D, Parada A, Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(–)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 2001;44:197-206
   PubMed Web of Science ®Google Scholar
• Mestre T, Ferreira JJ. Eslicarbazepine acetate: a new option for the treatment of focal epilepsy. Expert Opin Investig Drugs 2009;18:221-9
   PubMed Web of Science ®Google Scholar
• Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 2012;53:935-46
   PubMed Web of Science ®Google Scholar
• Ambrósio AF, Silva AP, Malva JO, et al. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 2001;61:1271-5
   PubMed Web of Science ®Google Scholar
• Hebeisen S, Pires N, Loureiro AI, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology 2015;89:122-35
   PubMed Web of Science ®Google Scholar
• Doeser A, Soares-da-Silva P, Beck H, Uebachs M. The effects of eslicarbazepine on persistent Na+ current and the role of the Na+ channel beta subunits. Epilepsy Res 2014;108:202-11
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gabbai AA, Hufnagel A, et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010;89:278-85
   PubMed Web of Science ®Google Scholar
• Elger C, Halász P, Maia J, et al. on behalf of the BIA-2093-30 I Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-63
   PubMed Web of Science ®Google Scholar
• Halász P, Cramer JA, Hodoba D, et al. on behalf of the BIA-2093-301 Study Group. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010;51:1963-9
   PubMed Web of Science ®Google Scholar
• Parada A, Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem Int 2002;40:435-40
   PubMed Web of Science ®Google Scholar
• Almeida L, Potgieter JH, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008;64:267-73
   PubMed Web of Science ®Google Scholar
• Almeida L, Falcão A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005;45:1062-6
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007;4:88-96
   PubMed Web of Science ®Google Scholar
• Keating GM. Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures. CNS Drugs 2014;28:583-600
   PubMed Web of Science ®Google Scholar
• Perucca E, Elger C, Halasz P, et al. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res 2011;96:132-9
   PubMed Web of Science ®Google Scholar
• Maia J, Vaz-da-Silva M, Almeida L, et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 2005;6:201-6
   PubMedGoogle Scholar
• Almeida L, Nunes T, Sicard E, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 2010;121:257-64
   PubMed Web of Science ®Google Scholar
• Loureiro AI, Fernandes-Lopes C, Bonifácio MJ, et al. Hepatic UDP-Glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Drug Metab Dispos 2011;39:1486-94
   PubMed Web of Science ®Google Scholar
• Falcão A, Maia J, Almeida L, et al. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007;28:249-56
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1-43
   PubMed Web of Science ®Google Scholar
• Italiano D, Perucca E. Clinical Pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet 2013;52:627-45
   PubMed Web of Science ®Google Scholar
• Almeida L, Minciu J, Nunes T, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol 2008;48:966-77
   PubMed Web of Science ®Google Scholar
• Maia J, Almeida L, Falcão A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008;46:119-30
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Zebinix (eslicarbazepine acetate): EU summary of product characteristics. 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000988/WC500047225.pdf
   Google Scholar
• Falcão A, Fuseau E, Nunes T, et al. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures. CNS Drugs 2012;26:79-91
   PubMed Web of Science ®Google Scholar
• Falcão A, Rocha JF, Pinto R, et al. Pharmacokinetic drug interaction study between eslicarbazepine acetate 1200 mg and phenytoin 300 mg: a phase I, open-label, multiple dose administration study in healthy volunteers. Epilepsia 2013;54:166
   Web of Science ®Google Scholar
• Jacobson M, Gidal BE, Kharidia J, et al. Effects of concomitant antiepileptic drugs on eslicarbazepine acetate: a population pharmacokinetic analysis. In: 67th Annual American Epilepsy Society Meeting; 6 – 10 December 2013; Washington, DC
   Google Scholar
• Nunes T, Sicard E, Almeida L, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 2010;26:1355-62
   PubMed Web of Science ®Google Scholar
• Falcão A, Vaz-da-Silva M, Gama H, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Res 2013;105:368-76
   PubMed Web of Science ®Google Scholar
• Vaz da Silva M, Almeida L, Falcão A, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther 2010;32:179-92
   PubMed Web of Science ®Google Scholar
• Falcão A, Pinto R, Nunes T, et al. Effects of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res 2013;106:244-9
   PubMed Web of Science ®Google Scholar
• Vaz da Silva M, Costa R, Soares E, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol 2009;23:509-14
   PubMed Web of Science ®Google Scholar
• Rocha JF, Vaz-da-Silva M, Almeida L, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther 2009;47:255-61
   PubMed Web of Science ®Google Scholar
• Pires N, Palma N, Loureiro AI, et al. Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the maximal electroconvulsive shock test in the mice. Epilepsia 2011;52:118
   Web of Science ®Google Scholar
• Potschka H, Soerensen J, Pekcec A, et al. Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy. Epilepsy Res 2014;108:212-22
   PubMed Web of Science ®Google Scholar
• Tarrão L, Machado R, Pires N, et al. Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine, and oxcarbazepine in the 6-Hz psychomotor seizure model in the mice. Epilepsia 2011;52:118-19
   Web of Science ®Google Scholar
• Sierra-Paredes G, Núñez-Rodriguez A, Vázquez-López A, et al. Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats. Epilepsy Res 2006;72:140-6
   PubMed Web of Science ®Google Scholar
• Sierra-Paredes G, Oreiro-García T, Vázquez-Illanes D, Sierra-Marcuño G. Effect of eslicarbazepine acetate (BIA 2-093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampus. Epilepsy Res 2007;77:36-43
   PubMed Web of Science ®Google Scholar
• Clinical Trials on Eslicarbazepine. Available from: https://clinicaltrials.gov/ct2/results?term =eslicarbazepine&Search=Search
   Google Scholar
• Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48:497-504
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, et al. on behalf of the BIA-2093-303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg Eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120:281-7
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Elger C, Ben-Menachem E, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013;54:98-107
   PubMed Web of Science ®Google Scholar
• Hufnagel A, Ben-Menachem E, Gabbai AA, et al. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res 2013;103:262-9
   PubMed Web of Science ®Google Scholar
• Correira FD, Freitas J, Magalhães R, et al. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study. Epilepsy Res 2014;108:1399-405
   PubMed Web of Science ®Google Scholar
• Villanueva V, Serratosa JM, Guillamón E, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res 2014;108:1243-52
   PubMed Web of Science ®Google Scholar
• Serrano-Castro PJ, Payán-Ortiz M, Cimadevilla JM, et al. Eslicarbazepine acetate in clinical practice. Efficacy and safety results. Rev Neurol 2013;56:309-14
   PubMed Web of Science ®Google Scholar
• Massot A, Vivanco R, Principe A, et al. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results. Neurologia 2014;29:94-101
   PubMed Web of Science ®Google Scholar
• Araújo I, Ambrósio A, Leal EC, et al. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia 2004;45:1498-505
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Maratea D, et al. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure 2013;22:528-36
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 2004;45:895-907
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Andres MM, Czuczwar SJ. Synergistic interaction of gabapentin and oxcarbazepine in the mouse maximal electroshock seizure model – an isobolographic analysis. Eur J Pharmacol 2005;515:54-61
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Andres MM, Czuczwar P, et al. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 2006;47:10-20
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Borowicz KK, Swiader M, Czuczwar SJ. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44:489-99
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Czuczwar M, Kis J, et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44:1003-13
   PubMed Web of Science ®Google Scholar
• Kwon OY, Park SP. Depression and anxiety in people with epilepsy. J Clin Neurol 2014;10:175-88
   PubMed Web of Science ®Google Scholar
• McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs 2009;23:71-9
   PubMed Web of Science ®Google Scholar